

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 97/30085 (43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number:	PCT/US97/02439	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ARPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	14 February 1997 (14.02.97)	
(30) Priority Data:	08/602,941 16 February 1996 (16.02.96) US	
(71) Applicant:	CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US).	
(72) Inventors:	MOSES, Marsha, A.; 64 Dean Road, Brookline, MA 02146 (US). LANGER, Robert, S.; 77 Lombard Street, Newton, MA 02158 (US). WIEDERSCHAIN, Dimitri, G.; 11 Stearns Road, Brookline, MA 02146 (US). WU, Inmin; 650 Huntington Avenue, Boston, MA 02115 (US). SYTKOWSKI, Arthur; 203 Park Avenue, Arlington, MA 02174 (US).	
(74) Agents:	POISSANT, Brian, M. et al.; Pennic & Edmonds L.L.P., 1155 Avenue of the Americas, New York, NY 10036 (US).	

(54) Title: TROPONIN SUBUNITS AND FRAGMENTS USEFUL AS ANGIOGENESIS INHIBITORS

(57) Abstract

The invention concerns methods of inhibiting atopic angiogenesis using troponin subunits and peptide fragments thereof. The invention further concerns pharmaceutical compositions comprising a troponin subunit or a fragment thereof. The pharmaceutical compositions and the methods of the invention are useful in the treatment of solid tumors, particularly tumors of the central nervous system and of the eye.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

AMENDED CLAIMS

[received by the International Bureau on 5 August 1997 (05.08.97);
original claims 1-23 replaced by new claims 1-17 (3 pages)]

1. A pharmaceutical composition comprising an amount of at least one peptide that is effective to inhibit angiogenesis and a pharmaceutically acceptable carrier therefor, characterized by the fact that the peptide is a troponin subunit selected from the group consisting of subunits C, I and T, or an analog or fragment thereof.
2. A pharmaceutical composition according to claim 1, characterized by the fact that the composition comprises additionally an effective amount of a molecule, other than said troponin subunit, which negatively regulates angiogenesis.
3. A pharmaceutical composition according to claim 1 or 2, characterized by the fact that the peptide is:
 - a. an inhibitor of bFGF-stimulated bovine endothelial cell proliferation having an IC₅₀ of at least 10 μM;
 - b. greater than 75 amino acids in length; and
 - c. greater than 80% homologous with a subunit selected from the group consisting of human fast-twitch troponin subunit C (SEQ ID No:1), human fast-twitch troponin subunit I (SEQ ID NO:2), and human fast-twitch troponin subunit T (SEQ ID NO:3).
4. A composition according to claim 3, characterized by the fact that the peptide is a mammalian troponin subunit selected from the group consisting of human, bovine, rabbit, mouse and rat troponin subunits.
5. A composition according to claim 3 or 4, characterized by the fact that the peptide is greater than 80% homologous with human fast-twitch troponin subunit C or human fast-twitch troponin subunit I.
6. A composition according to claim 3, characterized by the fact that the peptide is greater than 95% homologous with a human troponin subunit.

7. A composition according to claim 6, characterized by the fact that the human troponin subunit is human fast-twitch troponin subunit C, or human fast-twitch troponin subunit I.

8. A composition according to claim 3, characterized by the fact that the peptide is a fragment of a mammalian troponin subunit.

9. A composition according to claim 8, characterized by the fact that the peptide is a fragment of a troponin subunit C or troponin subunit I selected from the group consisting of human, bovine, rabbit, mouse and rat troponin subunit C and subunit I.

10. A composition according to any one of claims 1 to 9, characterized by the fact that the carrier is acceptable for topical application to the eye or to the skin.

11. A composition according to any one of claims 3 to 9, characterized by the fact that the angiogenesis inhibitor is in a biodegradable, biocompatible polymeric delivery device.

12. The use of a peptide in an amount effective to inhibit angiogenesis, characterized by the fact that the peptide is a troponin subunit selected from the group consisting of subunits C, I, and T, or an analog or fragment thereof.

13. The use according to claim 12, characterized by the fact that the peptide is:

- an inhibitor of bFGF-stimulated bovine endothelial cell proliferation having an IC₅₀ of at least 10 μM;
- greater than 75 amino acids in length; and
- greater than 80% homologous with a subunit selected from the group consisting of human fast-twitch troponin subunit C (SEQ ID NO:1), human fast-twitch troponin subunit I (SEQ ID NO:2), and human fast-twitch troponin subunit T (SEQ ID NO:3).

14. A method of inhibiting angiogenesis in a subject having a disease or disorder associated with angiogenesis which comprises administering to said subject an effective amount of a peptide, characterized by the fact that the peptide is a troponin subunit selected from the group consisting of subunits C, I and T, or an analog or fragment thereof.

15. A method according to claim 14, characterized by the fact that the peptide is:

- a. an inhibitor of bFGF-stimulated bovine endothelial cell proliferation having an IC₅₀ of at least 10 μM;
- b. greater than 75 amino acids in length; and
- c. greater than 80% homologous with a subunit selected from the group consisting of human fast-twitch troponin subunit C (SEQ ID NO:1), human fast-twitch troponin subunit I (SEQ ID NO:2), and human fast-twitch troponin subunit T (SEQ ID NO:3).

16. A method according to claim 15, characterized by the fact that the peptide is greater than 80% homologous with human fast-twitch troponin subunit C or human fast-twitch troponin subunit I.

17. A method according to claim 15 or 16, characterized by the fact that the disease or disorder is a solid tumor, or a tumor of the central nervous system, or an ophthalmologic disease or disorder.

221:269-283. There is therefore a great need for the further identification and characterization of chemical agents which can prevent the continued deregulated spread of vascularization and which would potentially have broad 5 applicability as a therapy for those diseases in which neovascularization plays a prominent role.

Capillary endothelial cells ("EC") proliferate in response to an angiogenic stimulus during neovascularization. Ausprunk and Folkman, 1977, *J. Microvasc. Res.* 14:153-65. An 10 *in vitro* assay assessing endothelial cell proliferation in response to known angiogenesis simulating factors, such as acidic or basic fibroblast growth factor (aFGF and bFGF, respectively), has been developed to mimic the process of neovascularization *in vitro*. This type of assay is the assay 15 of choice to demonstrate the stimulation of capillary EC proliferation by various angiogenic factors. Shing et al., 1984, *Science* 223:1296-1298.

The process of capillary EC migration through the extracellular matrix towards an angiogenic stimulus is also 20 a critical event required for angiogenesis. See, e.g., review by Ausprunk et al., 1977, *J. Microvasc. Res.* 14:53-65. This process provides an additional assay by which to mimic the process of neovascularization *in vitro*. A modification of the Boyden chamber technique has been developed to monitor EC 25 migration. Boyden et al., 1962, *J. Exptl. Med.* 115:453-456, Example 4. To date, only a few tissue-derived EC cell migration inhibitors are known. See, e.g., review by Langer et al., 1976, *Science* 193:70-72.

In the early 1970's, a number of *in vivo* 30 angiogenesis model bioassays were widely used. These model systems included rabbit corneal pocket, chick chorioallantoic membrane ("CAM"), rat dorsal air sac and rabbit air chamber bioassays. For review, see, Blood et al., 1990, *Biochem. et Biophys. Acta* 1032:89-118. The development of controlled 35 release polymers capable of releasing large molecules such as angiogenesis stimulators and inhibitors was critical to the

use of these assays. Langer et al., 1976, *Nature* 263:797-800.

In the CAM bioassay, fertilized chick embryos are cultured in Petri dishes. On day 6 of development, a disc of 5 a release polymer, such as methyl cellulose, impregnated with the test sample or an appropriate control substance is placed onto the vascular membrane at its advancing edge. On day 8 of development, the area around the implant is observed and evaluated. Avascular zones surrounding the test implant 10 indicate the presence of an inhibitor of embryonic neovascularization. Moses et al., 1990, *Science*, 248:1408-1410 and Taylor et al., 1982, *Nature*, 297:307-312. The reported doses for previously described angiogenesis inhibitors tested alone in the CAM assay are 50 µg of 15 protamine (Taylor et al. (1982)), 200 µg of bovine vitreous extract (Lutty et al., 1983, *Invest. Ophthalmol. Vis. Sci.* 24:53-56), and 10 µg of platelet factor IV (Taylor et al. (1982)). The lowest reported doses of angiogenesis inhibitors effective as combinations include heparin (50 µg) 20 and hydrocortisone (60 µg), and B-cyclodextrin tetradecasulfate (14 µg) and hydrocortisone (60 µg), reported by Folkman et al., 1989, *Science* 243:1490.

According to the rabbit corneal pocket assay, polymer pellets of ethylene vinyl acetate copolymer ("EVAC") 25 are impregnated with test substance and surgically implanted in a pocket in the rabbit cornea approximately 1 mm from the limbus. Langer et al., 1976, *Science* 193:707-72. To test for an angiogenesis inhibitor, either a piece of carcinoma or some other angiogenic stimulant is implanted distal to the 30 polymer 2 mm from the limbus. In the opposite eye of each rabbit, control polymer pellets that are empty are implanted next to an angiogenic stimulant in the same way. In these control corneas, capillary blood vessels start growing towards the tumor implant in 5-6 days, eventually sweeping 35 over the blank polymer. In test corneas, the directional growth of new capillaries from the limbal blood vessel towards the tumor occurs at a reduced rate and is often

inhibited such that an avascular region around the polymer is observed. This assay is quantitated by measurement of the maximum vessel lengths with a stereospecific microscope.

Troponin, a complex of three polypeptides is an accessory protein that is closely associated with actin filaments in vertebrate muscle. The troponin complex, acts in conjunction with the muscle form of tropomyosin to mediate the Ca^{2+} dependency of myosin ATPase activity and thereby regulate muscle contraction. The troponin polypeptides T, I, and C, are named for their tropomyosin binding, inhibitory, and calcium binding activities, respectively. Troponin T binds to tropomyosin and is believed to be responsible for positioning the troponin complex on the muscle thin filament. Troponin I binds to actin, and the complex formed by troponins I and T, and tropomyosin, inhibits the interaction of actin and myosin. Troponin C is capable of binding up to four calcium molecules. Studies suggest that when the level of calcium in the muscle is raised, troponin C causes troponin I to loose its hold on the actin molecule, causing the tropomyosin molecule shift, thereby exposing the myosin binding sites on actin and stimulating myosin ATPase activity. Prior to the discovery of the present invention, troponin subunits were not known to inhibit the process of endothelial cell proliferation.

The citation of a reference herein shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention relates to pharmaceutical compositions containing troponin subunits C, I, or T, or fragments thereof, in therapeutically effective amounts that are capable of inhibiting endothelial cell proliferation. The invention also relates to pharmaceutical compositions containing analogs of troponin subunits C, I, or T and analogs of their fragments, in therapeutically effective amounts that are capable of inhibiting endothelial cell

proliferation. The invention further relates to treatment of neovascular disorders by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics"), include: troponin subunits 5 C, I, and T, and fragments and analogs thereof. In one embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from the pre-neoplastic or pre-malignant state into a neoplastic or a malignant state. In other specific embodiments, a 10 Therapeutic of the invention is administered to treat ocular disorders associated with neovascularization.

3.1. Definitions

As used herein, :

15 The term "troponin subunit", when not preceding the terms C, I or T, means generically any of troponin subunits C, I, or T.

4. BRIEF DESCRIPTION OF THE FIGURES

20 **Figure 1.** Inhibition of bovine capillary Endothelial Cell (BCE) proliferation by troponin C. Percent inhibition of bFGF-stimulated BCE proliferation is shown as a function of troponin C concentration (nM). Percent inhibition was determined by comparing results obtained for 25 cells treated with stimulus alone with those obtained for samples exposed to both stimulus and inhibitor. Well volume was 200 μ l.

Figure 2. Inhibition of capillary BCE proliferation by troponin I. Percent inhibition of 30 bFGF-stimulated BCE proliferation is shown as a function of troponin I concentration (nM). Percent inhibition was determined as described in Figure 1. Well volume was 200 μ l.

Figure 3. Inhibition of capillary BCE proliferation by troponin T. Percent inhibition of 35 bFGF-stimulated BCE proliferation is shown as a function of troponin T concentration (nM). Percent inhibition was determined as described in Figure 1. Well volume was 200 μ l.

Figure 4. Inhibition of BCE proliferation by troponins C and I. Percent inhibition of bFGF-stimulated BCE proliferation is shown as a function of troponin I and C concentration (nM). Percent inhibition was determined as described in Figure 1. Well volume was 200 μ l.

Figure 5. Inhibition of capillary BCE proliferation by troponin C, I and T. Percent inhibition of bFGF-stimulated BCE proliferation is shown as a function of troponin C, I, and T concentration (nM). Percent inhibition was determined as described in Figure 1. Well volume was 200 μ l.

Figure 6. Inhibition of tumor growth in SCID mice.

5. DETAILED DESCRIPTION OF THE INVENTION

15 The present invention relates to therapeutic methods and compositions based on troponin subunits. The invention provides for treatment of neovascular disorders by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics")
20 include: troponin C, I, and T subunits, fragments and analogs thereof (collectively "peptides of the invention"). The peptides of the invention are characterized by the property of inhibiting bovine endothelial cell proliferation in culture with an IC₅₀ of 10 μ M or less. In a preferred
25 embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from a pre-neoplastic or non-malignant state into a neoplastic or a malignant state. In other specific embodiments, a Therapeutic of the invention is administered to treat an
30 ocular disorder associated with neovascularization.

In a preferred aspect, a Therapeutic of the invention is a peptide consisting of at least a fragment of troponin C, troponin I, troponin T, or troponins C and I, which is effective to inhibit endothelial cell proliferation.

35 Examples of the troponin subunits that can be utilized in accordance with the invention, include the

subunits of troponin from human fast twitch skeletal muscle, the sequences of which are given below:

Human Fast Twitch Skeletal Muscle Troponin C (SEQ ID NO:1)

5	1	M	T	D	Q	Q	A	E	A	R	S	Y	L	S	E	E	M	I	A	E	F
21	K	A	A	F	D	M	F	D	A	D	G	G	G	D	I	S	V	K	E	L	
41	G	T	V	M	R	M	L	G	Q	T	P	T	K	E	E	L	D	A	I	M	
61	E	E	V	D	E	D	G	S	G	T	I	D	F	E	E	F	L	A	V	M	
81	V	R	Q	M	K	E	D	A	K	G	K	S	E	E	E	L	A	E	C	F	
101	R	I	F	D	R	N	A	D	G	Y	I	D	P	E	E	L	A	E	I	F	
121	R	A	S	G	E	H	V	T	D	E	E	I	E	S	L	M	K	D	G		
141	K	N	N	D	G	R	I	D	F	D	E	F	L	K	M	M	E	G	V		
10	141																			Q	

Human Fast Twitch Skeletal Muscle Tropomin I (SEQ ID NO:2)

1	M	G	D	E	E	K	R	N	R	A	I	T	A	R	R	Q	H	L	K	S
21	V	M	L	Q	I	A	A	T	E	L	E	K	E	E	S	R	R	E	A	S
41	K	Q	N	Y	L	A	E	H	C	P	P	L	H	I	P	G	S	M	E	Y
61	V	Q	E	L	C	K	Q	L	H	A	K	I	D	A	A	E	E	E	K	K
81	D	M	E	V	R	V	Q	K	T	S	K	E	L	E	D	M	N	Q	K	L
101	F	D	L	R	G	K	F	K	R	P	P	L	R	R	V	R	M	S	A	D
121	A	M	L	K	A	L	L	G	S	K	H	K	V	C	M	D	L	R	V	
141	L	K	Q	V	K	K	E	D	T	E	K	E	R	D	L	R	D	M	F	
161	W	R	K	N	I	E	E	K	S	G	M	E	G	R	K	K	M	F	E	
181	E	S																		D
15																				S

20

Human Fast Skeletal Beta Troponin T (SEQ ID NO:3)

1	M	S	D	E	E	V	E	Q	V	E	E	Q	Y	E	E	E	E	A	Q
21	E	E	E	E	V	Q	E	D	T	A	E	E	D	A	E	E	E	K	R
41	P	K	L	T	A	P	K	I	P	E	G	E	K	V	D	F	D	D	Q
61	K	K	R	Q	N	K	D	L	M	E	L	Q	A	L	I	D	S	H	
81	A	R	K	K	E	E	E	E	L	V	A	L	K	E	R	I	E	K	
101	A	E	R	A	E	Q	Q	R	I	R	A	E	K	E	R	E	R	Q	
121	L	A	E	E	K	A	R	R	E	E	E	D	A	K	R	R	A	Y	
141	L	K	K	K	A	L	S	S	M	G	A	R	E	N	Y	S	S	A	
161	A	D	Q	K	R	G	K	K	Q	T	H	A	G	E	M	K	K	I	
181	E	R	R	K	P	L	N	I	D	H	L	E	I	D	K	F	R	D	
201	K	E	L	W	E	T	L	H	Q	L	E	I	D	K	F	E	R	Q	
221	L	K	R	Q	K	Y	D	I	T	T	L	R	S	R	I	D	R	G	
241	H	S	K	K	A	G	T	P	A	K	G	K	V	G	G	R	W	K	
30																			

35

In another embodiment, the invention encompasses peptides which are homologous to human fast-twitch skeletal troponin C (SEQ ID NO:1) or fragments thereof. In one embodiment, the amino acid sequence of the peptide has at least 80% identity compared to the fragment of human fast-twitch skeletal troponin C from which it is derived (the "prototype fragment"). In another embodiment, this identity is greater than 85%. In a more preferred embodiment, this identity is greater than 90%. In a most preferred embodiment, the amino acid sequence of the peptide has at least 95% identity with the prototype fragment. Fragments can be at least 10 amino acids, and in preferred embodiments at least 50, 75, 100 and 120 amino acids, respectively.

In another embodiment, the invention encompasses peptides which are homologous to human fast-twitch skeletal troponin I (SEQ ID NO:2) or fragments thereof. In one embodiment, the amino acid sequence of the peptide has at least 80% identity with the prototype human fast-twitch skeletal troponin I fragment. In another embodiment, this identity is greater than 85%. In a more preferred embodiment, this identity is greater than 90%. In a most preferred embodiment, the amino acid sequence of the peptide has at least 95% identity with the prototype fragment. Fragments can be at least 10 amino acids, and in preferred embodiments at least 50, 75, 100 and 120 amino acids, respectively.

In another embodiment, the invention encompasses peptides which are homologous to human fast-twitch skeletal troponin T (SEQ ID NO:3) or fragments thereof. In one embodiment, the amino acid sequence of the peptide has at least 80% identity with the prototype human fast-twitch skeletal beta troponin T. In another embodiment, this identity is greater than 85%. In a more preferred embodiment, this identity is greater than 90%. In a most preferred embodiment, the amino acid sequence of the peptide has at least 95% identity with the prototype fragment. Fragments can be at least 10 amino acids, and in preferred

embodiments at least 50, 75, 100, 120 and 200 amino acids in length, respectively.

In other specific embodiments, the peptides of the invention are troponin C, troponin I and troponin T subunits 5 of the fast twitch, slow twitch and cardiac isoforms from other mammalian species, e.g., human, rabbit, rat, mouse, bovine, ovine and porcine.

In a specific embodiment, a Therapeutic of the invention is combined with a therapeutically effective amount 10 of another molecule which negatively regulates angiogenesis which may be, but is not limited to, platelet factor 4, thrombospondin-1, tissue inhibitors of metalloproteases (TIMP1 and TIMP2) prolactin (16-Kd fragment), angiostatin (38-Kd fragment of plasminogen), bfGf soluble receptor, 15 transforming growth factor β , interferon alfa, and placental proliferin-related protein.

Paradoxically, neovascularization gradually reduces a tumors accessibility to chemotherapeutic drugs due to increased interstitial pressure within the tumor, which 20 causes vascular compression and central necrosis. *In vivo* results have demonstrated that rodents receiving angiogenic therapy show increased delivery of chemotherapy to a tumor. Teicher et al., 1994, *Int. J. Cancer* 57:920-925. Thus, in one embodiment, the invention provides for a pharmaceutical 25 composition of the present invention in combination with a chemotherapeutic agent.

In another preferred aspect, a Therapeutic of the invention is combined with chemotherapeutic agents or radioactive isotope exposure.

30 The invention is illustrated by way of examples *infra* which disclose, *inter alia*, the inhibition of capillary endothelial cell proliferation by troponin subunits C, I, and T and the means for determining inhibition of capillary endothelial cell migration and inhibition of 35 neovascularization *in vivo* by troponin subunits.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections set forth below.

5 5.1. TROPONIN SUBUNITS, FRAGMENTS AND ANALOGS

The invention provides for pharmaceutical compositions comprising troponin subunits, fragments, and analogs thereof. In particular aspects, the subunits, fragments, or analogs are of fly, frog, mouse, rat, rabbit, 10 pig, cow, dog, monkey, or human troponin subunits.

It is envisioned that troponin subunit fragments can be made by altering troponin sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. These include, but are not limited to, 15 troponin subunits, fragments, or analogs containing, as a primary amino acid sequence, all or part of the amino acid sequence of a troponin subunit including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a 20 silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members 25 of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, 30 asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

One embodiment of the invention provides for 35 molecules consisting of or comprising a fragment of at least 10 (continuous) amino acids of a troponin subunit which is capable of inhibiting endothelial cell proliferation. In

other embodiments, this molecule consists of at least 20 or 50 amino acids of the troponin subunit. In specific embodiments, such molecules consist of or comprise fragments of a troponin subunit that at least 75, 120 or 200 amino acids.

In a preferred embodiment, the protein is a mammalian troponin subunit. In alternative embodiments, it is a mammalian troponin C, I, or T subunit.

The troponin subunit fragments and analogs of the invention can be derived from tissue (see, for example, Example 1; Ebashi et al., 1968, *J. Biochem.* 64:465; Yasui et al., 1968, *J. Biol. Chem.* 243:735; Hartshorne et al., 1968, *Biochem. Biophys. Res. Commun.* 31:647; Shaub et al., 1969, *Biochem. J.* 115:993; Greaser et al., 1971, *J. Biol. Chem.* 246:4226-4733; Brekke et al., 1976, *J. Biol. Chem.* 251:866-871; and Yates et al., 1983, *J. Biol. Chem.* 258:5770-5774) or produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, a cloned troponin gene sequence coding for troponin subunits C, I, or T, can be modified by any of numerous strategies known in the art. Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of a troponin subunit, care should be taken to ensure that the modified gene remains within the same translational reading frame as the troponin subunit gene, uninterrupted by translational stop signals, in the gene region where the desired troponin activity is encoded.

Additionally, the troponin subunit encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy

preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 5 253:6551), use of TAB[®] linkers (Pharmacia), etc.

Manipulations of troponin subunit C, I, or T sequence may also be made at the protein level. Included within the scope of the invention are troponin subunit fragments or other fragments or analogs which are 10 differentially modified during or after translation, e.g., by acetylation, phosphorylation, carboxylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical 15 modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, etc.

In addition, fragments and analogs of troponin 20 subunits can be chemically synthesized. For example, a peptide corresponding to a portion of a troponin subunit which comprises the desired domain, or which mediates the desired activity *in vitro*, can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical 25 amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the troponin subunit sequence. Non-classical amino acids include, but are not limited to, the D-isomers of the common amino acids, α -amino isobutyric acid, 4-aminobutyric acid, hydroxyproline, 30 sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, designer amino acids such as β -methyl amino acids, $\text{C}\alpha$ -methyl amino acids, and $\text{N}\alpha$ -methyl amino acids.

In a specific embodiment, the invention encompasses 35 a chimeric, or fusion, protein comprising a troponin subunit or fragment thereof (consisting of at least a domain or motif of the troponin subunit that is responsible for inhibiting

endothelial cell proliferation) joined at its amino or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein. Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding 5 the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.

10

5.2. ASSAYS OF TROPONIN PROTEINS FRAGMENTS AND ANALOGS

The functional activity and/or therapeutically effective dose of troponin subunits, fragments and analogs, 15 can be assayed *in vitro* by various methods. These methods are based on the physiological processes involved in angiogenesis and while they are within the scope of the invention, they are not intended to limit the methods by which troponin subunits, fragments and analogs inhibiting 20 angiogenesis are defined and/or a therapeutically effective dosage of the pharmaceutical composition is determined.

For example, where one is assaying for the ability 25 of troponin subunits, fragments, and analogs, to inhibit or interfere with the proliferation of capillary endothelial cells (EC) *in vitro*, various bioassays known in the art can be used, including, but not limited to, radioactive incorporation into nucleic acids, colorimetric assays and cell counting.

Inhibition of endothelial cell proliferation may be 30 measured by colorimetric determination of cellular acid phosphatase activity or electronic cell counting. These methods provide a quick and sensitive screen for determining the number of endothelial cells in culture after treatment with the troponin subunit, derivative, or analog of the 35 invention, and an angiogenesis stimulating factor such as aFGF. The colorimetric determination of cellular acid phosphatase activity is described by Connolly et al., 1986,

J. Anal. Biochem. 152:136-140. According to this method, described in Example 3, capillary endothelial cells are treated with angiogenesis stimulating factors, such as aFGF, and a range of potential inhibitor concentrations. These 5 samples are incubated to allow for growth, and then harvested, washed, lysed in a buffer containing a phosphatase substrate, and then incubated a second time. A basic solution is added to stop the reaction and color development is determined at 405 λ . According to Connolly et al., a 10 linear relationship is obtained between acid phosphatase activity and endothelial cell number up to 10,000 cells/sample. Standard curves for acid phosphatase activity are also generated from known cell numbers in order to confirm that the enzyme levels reflect the actual EC numbers. 15 Percent inhibition is determined by comparing the cell number of samples exposed to stimulus with those exposed to both stimulus and inhibitor.

Colorimetric assays to determine the effect of troponin subunits C, I, and T on endothelial cell 20 proliferation demonstrate that all three troponin subunits interfere with bFGF-stimulated endothelial cell proliferation.

Troponin C inhibited bFGF-stimulated endothelial cell proliferation in a dose-dependent manner in all 25 concentrations tested (FIG 1). Percent inhibition of bovine endothelial cell proliferation ("BCE") was 54%, 86%, 83%, and 100% at concentrations of 280 nM, 1.4 μ M, 2.8 μ M and 5.6 μ M, respectively. An inhibition of 100% was observed at a concentration of 20 μ g/well (5.6 μ M). IC_{50} represents the 30 concentration at which 50% inhibition of aFGF growth factor-induced stimulation was observed. The IC_{50} of troponin C was determined to be 278 nM.

Troponin I inhibited bFGF-stimulated BCE proliferation at concentrations of 1 and 5 μ g/well, but 35 inhibition was not observed in the sample tested at 10 μ g/well (FIG 2). The percent inhibition of BCE was 33% and

46% at concentrations of 240 nM and 1.2 μ M, respectively. The IC₅₀ of troponin I was determined to be 1.14 μ M.

Troponin T inhibited bFGF-stimulated EC proliferation at concentrations of 10 and 20 μ g/well, but not 5 at concentrations of 1 and 5 μ g/well (FIG 3). BCE proliferation was inhibited 23% and 62% at 1.6 μ M and 3.3 μ M, respectively. The IC₅₀ of troponin T was determined to be 2.14 μ M.

The combination of troponin subunits C and I 10 inhibited EC at all concentrations tested (FIG 4). The percent inhibition of BCE was 52%, 54% 73% and 47% at 130 nM, 645 nM, 1.3 μ M and 2.6 μ M, respectively. The IC₅₀ of this combination was determined to be 110 nM.

The combination of troponin subunits C, I and T was 15 observed to inhibit aFGF stimulated BCE proliferation by 16% at a concentration of 360 nM (5 μ g/well, FIG 5).

The troponins samples tested had no detectable inhibitory effect on the growth of Balb/c 3T3 cells, a non-endothelial cell type.

20 The incorporation of radioactive thymidine by capillary endothelial cells represents another means by which to assay for the inhibition of endothelial cell proliferation by a potential angiogenesis inhibitor. According to this method, a predetermined number of capillary endothelial cells 25 are grown in the presence of ³H-Thymidine stock, an angiogenesis stimulator such as for example, bFGF, and a range of concentrations of the angiogenesis inhibitor to be tested. Following incubation, the cells are harvested and the extent of thymidine incorporation is determined. See, 30 Example 2.

The ability of varying concentrations of troponin subunits, fragments or analogs to interfere with the process of capillary endothelial cell migration in response to an angiogenic stimulus can be assayed using the modified Boyden 35 chamber technique. See, Section 2 and Example 4, *infra*.

Another means by which to assay the functional activity of troponin subunits, fragments and analogs,

involves examining the ability of the compounds to inhibit the directed migration of capillary endothelial cells which ultimately results in capillary tube formation. This ability may be assessed for example, using an assay in which 5 capillary endothelial cells plated on collagen gels are challenged with the inhibitor, and determining whether capillary-like tube structures are formed by the cultured endothelial cells.

Assays for the ability to inhibit angiogenesis in *vivo* include the chick chorioallantoic membrane assay (see 10 Section 2 and Example 5, *infra*) and rat or rabbit corneal pocket assays. See, Polverini et al., 1991, *Methods Enzymol.* 198:440-450. According to the corneal pocket assays, a tumor of choice is implanted into the cornea of the test animal in 15 the form of a corneal pocket. The potential angiogenesis inhibitor is applied to the corneal pocket and the corneal pocket is routinely examined for neovascularization. See, Section 2 and Example 6 *infra*.

One embodiment of the invention provides for 20 combination of the troponin subunits, fragments, or analogs of the present invention to inhibit angiogenesis. Another embodiment provides for the combination of troponin subunits, fragments, or analogs with other angiogenesis inhibiting factors. Such angiogenesis inhibiting factors include, but 25 are not limited to: angiotropic steroids, thrombospondin, platelet factor IV, transforming growth factor β , interferons, tumor necrosis factor α , bovine vitreous extract, protamine, tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), prolactin (16-kd fragment), angiostatin 30 (38-kd fragment of plasminogen), bFGF soluble receptor, and placental proliferin-related protein. See, e.g., reviews by Folkman et al., 1995, *N. Engl. J. Med.* 333:1757-1763 and Klagsbrun et al., 1991, *Annu. Rev. Physiol.* 53:217-239.

The therapeutically effective dosage for inhibition 35 of angiogenesis *in vivo*, defined as inhibition of capillary endothelial cell proliferation, migration, and/or blood vessel ingrowth, may be extrapolated from *in vitro* inhibition

assays using the compositions of the invention above or in combination with other angiogenesis inhibiting factors. The effective dosage is also dependent on the method and means of delivery. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical-ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant. The protein can also be modified, for example, by polyethyleneglycol treatment.

5.3. THERAPEUTIC USES

The invention provides for treatment of diseases or disorders associated with neovascularization by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include troponin subunits and fragments and analogs thereof (e.g., as described *infra*).

20

5.3.1. MALIGNANCIES

Malignant and metastatic conditions which can be treated with the Therapeutic compounds of the present invention include, but are not limited to, the solid tumors listed in Table 1 (for a review of such disorders, see Fishman et al., 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia) :

30

35

TABLE 1
MALIGNANCIES AND RELATED DISORDERS

	Solid tumors
5	sarcomas and carcinomas fibrosarcoma myxosarcoma liposarcoma chondrosarcoma osteogenic sarcoma chordoma
10	angiosarcoma endothelirosarcoma lymphangiosarcoma lymphangioendothelirosarcoma synovioma mesothelioma Ewing's tumor leiomyosarcoma
15	rhabdomyosarcoma colon carcinoma pancreatic cancer breast cancer ovarian cancer prostate cancer squamous cell carcinoma
20	basal cell carcinoma adenocarcinoma sweat gland carcinoma sebaceous gland carcinoma papillary carcinoma papillary adenocarcinomas cystadenocarcinoma medullary carcinoma
25	bronchogenic carcinoma renal cell carcinoma hepatoma bile duct carcinoma choriocarcinoma seminoma embryonal carcinoma
30	Wilms' tumor cervical cancer testicular tumor lung carcinoma small cell lung carcinoma bladder carcinoma epithelial carcinoma glioma
35	astrocytoma medulloblastoma craniopharyngioma ependymoma

Kaposi's sarcoma
pinealoma
hemangioblastoma
acoustic neuroma
oligodendroglioma
menangioma
5 melanoma
neuroblastoma
retinoblastoma

5.3.2. OCULAR DISORDERS

10 Ocular disorders associated with neovascularization which can be treated with the Therapeutic compounds of the present invention include, but are not limited to:

15 neovascular glaucoma
diabetic retinopathy
retinoblastoma
retrolental fibroplasia
uveitis
retinopathy of prematurity
macular degeneration
corneal graft neovascularization

20 as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman et al., 1978, *Am. J. Ophthal.* 85:704-710 and Gartner et al., 1978, *Surv. Ophthal.* 22:291-312.

25

5.3.3. OTHER DISORDERS

Other disorders which can be treated with the Therapeutic compounds of the present invention include, but are not limited to, hemangioma, arthritis, psoriasis, 30 angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

**5.4. DEMONSTRATION OF THERAPEUTIC
OR PROPHYLACTIC UTILITY**

The Therapeutics of the invention can be tested *in vivo* for the desired therapeutic or prophylactic activity as well as for determination of therapeutically effective dosage. For example, such compounds can be tested in suitable animal model systems prior to testing in humans, including, but not limited to, rats, mice, chicken, cows, monkeys, rabbits, etc. For *in vivo* testing, prior to administration to humans, any animal model system known in the art may be used.

**5.5. THERAPEUTIC/PROPHYLACTIC
ADMINISTRATION AND COMPOSITIONS**

The invention provides methods of treatment (and prophylaxis) by administration to a subject an effective amount of a Therapeutic of the invention. In a preferred aspect, the Therapeutic is substantially purified as set forth in Example 1. The subject is preferably an animal, including, but not limited to, animals such as cows, pigs, chickens, etc., and is preferably a mammal, and most preferably human.

The invention further provides methods of treatment by administration to a subject, an effective amount of a Therapeutic of the invention combined with a chemotherapeutic agent and/or radioactive isotope exposure.

The invention also provides for methods of treatment of a Therapeutic of the invention for patients who have entered a remission in order to maintain a dormant state.

Various delivery systems are known and can be used to administer a Therapeutic of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432). Methods of introduction include, but are not limited to, topical, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,

epidural, ophthalmic, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and 5 intestinal mucosa, etc.) and may be administered together with other biologically active agents. It is preferred that administration is localized, but it may be systemic. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system 10 by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use 15 of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be 20 achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, 25 non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

30 For topical application, the purified troponin subunit is combined with a carrier so that an effective dosage is delivered, based on the desired activity (i.e., ranging from an effective dosage, for example, of 1.0 μ M to 1.0 mM to prevent localized angiogenesis, endothelial cell 35 migration, and/or inhibition of capillary endothelial cell proliferation. In one embodiment, a topical troponin subunit, fragment or analog is applied to the skin for

treatment of diseases such as psoriasis. The carrier may in the form of, for example, and not by way of limitation, an ointment, cream, gel, paste, foam, aerosol, suppository, pad or gelled stick.

5 A topical Therapeutic for treatment of some of the eye disorders discussed *infra* consists of an effective amount of troponin subunit, fragment, or analog, in a ophthalmologically acceptable excipient such as buffered saline, mineral oil, vegetable oils such as corn or arachis 10 oil, petroleum jelly, Miglyol 182, alcohol solutions, or liposomes or liposome-like products. Any of these compositions may also include preservatives, antioxidants, antibiotics, immunosuppressants, and other biologically or pharmaceutically effective agents which do not exert a 15 detrimental effect on the troponin subunit.

For directed internal topical applications, for example for treatment of ulcers or hemorrhoids, the troponin subunit, fragment, or analog composition may be in the form of tablets or capsules, which can contain any of the 20 following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; 25 or a glidant such as colloidal silicon dioxide. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage 30 unit, for example, coatings of sugar, shellac, or other enteric agents.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

35 In another embodiment, the Therapeutic can be delivered in a vesicle, in particular a liposome. See, Langer et al., 1990, *Science* 249:1527-1533; Treat et al.,

1989, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365; Lopez-Berestein, *ibid.*, pp. 317-327.

In yet another embodiment, the Therapeutic can be
5 delivered in a controlled release system. In one embodiment,
an infusion pump may be used to administer troponin subunit,
such as for example, that used for delivering insulin or
chemotherapy to specific organs or tumors (see Langer, *supra*;
Sefton, *CRC Crit. Ref. Biomed.*, 1987, Eng. 14:201; Buchwald
10 et al., 1980, *Surgery* 88:507; Saudek et al., 1989, *N. Engl. J. Med.* 321:574.

In a preferred form, the troponin subunit,
fragment, or analog is administered in combination with a
biodegradable, biocompatible polymeric implant which releases
15 the troponin subunit, fragment, or analog over a controlled
period of time at a selected site. Examples of preferred
polymeric materials include polyanhydrides, polyorthoesters,
polyglycolic acid, polylactic acid, polyethylene vinyl
acetate, and copolymers and blends thereof. See, *Medical*
20 *Applications of Controlled Release*, Langer and Wise (eds.),
1974, CRC Pres., Boca Raton, Florida; *Controlled Drug
Bioavailability, Drug Product Design and Performance*, Smolen
and Ball (eds.), 1984, Wiley, New York; Ranger and Peppas,
1983, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61; see also
25 Levy et al., 1985, *Science* 238:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105.
In yet another embodiment, a controlled release system can be
placed in proximity of the therapeutic target, i.e., the
brain, thus requiring only a fraction of the systemic dose
30 (see, e.g., Goodson, in *Medical Applications of Controlled
Release*, 1989, *supra*, vol. 2, pp. 115-138).

Other controlled release systems are discussed in
the review by Langer (1990, *Science* 249:1527-1533).

The present invention also provides pharmaceutical
35 compositions. Such compositions comprise a therapeutically
effective amount of a Therapeutic, and a pharmaceutically
acceptable carrier.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, 5 oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

10 In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The 15 term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral 20 oil, sesame oil and the like, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be 25 employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, 30 glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents such as acetates, citrates or phosphates. Antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such 35 as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; and agents for the adjustment of tonicity such as sodium chloride or dextrose

are also envisioned. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

These compositions can take the form of solutions, 5 suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides, microcrystalline cellulose, gum tragacanth or gelatin. Oral formulation can 10 include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such 15 compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

20 In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic 25 aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry 30 lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile 35 pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for

injection or saline can be provided so that the ingredients may be mixed prior to administration.

The amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays such as those discussed in section 5.2 may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test bioassays or systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Modifications and variations of the compositions of the present invention, and methods for use, will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to fall within the scope of the appended claims.

The following non-limiting examples demonstrate the discovery of troponin subunit inhibition of angiogenic stimulus induced endothelial cell proliferation, and means

for determining the effective dosage of troponin subunit, fragment, or analog to inhibit angiogenesis, as well as for identifying troponin subunit fragments and analogs (i.e., those fragments or analogs of troponin subunit capable of 5 inhibiting angiogenesis. The troponin subunit used in the examples is purified as described *infra*.

6. EXAMPLES

10 Example 1: Purification of Troponin subunit Components

Cardiac Troponin Isolation from Tissue

The procedures of Ebashi et al., 1968, *J. Biochem.* 64:465-477; Yasui et al., 1968, *J. Biol. Chem.* 243:735-742; 15 Hartshorne et al., 1969, *Biochim. Biophys. Acta*, 175:30; Schaub et al., 1969, *Biochem. J.* 115:993-1004; Greaser et al., 1971, *J. Biol. Chem.* 246:4226-4233; and Greaser et al., 1973, *J. Biol. Chem.* 248:2125-2133 for purifying troponin can be used. Rabbit back and leg muscles are removed, cleaned of 20 fat and connective tissue, and ground. The ground muscle (1 kg) is stirred for 5 min. in 2 liters of a solution containing 20 mM KCl, 1 mM KHCO₃, 0.1 mM CaCl₂, and 0.1 mM DTT. The suspension is filtered through cheesecloth, and the washing of the residue is repeated four times. Two 25 liters of 95% ethanol are then added to the washed residue and the solution filtered after 10 min. The ethanol extraction is repeated twice. The residue is then washed 3 times with 2 liters of diethyl ether for 10 min. Finally the residue is allowed to dry at room temperature for 2 to 3 30 hours.

The dried powder (from 1 kg of muscle) is extracted overnight at 22° with 2 liters of a solution containing 1 M KCl, 25 mM Tris (pH 8.0), 0.1 mM CaCl₂, and 1 mM DTT. After

35 The abbreviations used are: DDT, dithiothreitol; EGTA, ethylene glycol bis(β-aminoethyl ether)-N,N'-tetraacetate; SDS, sodium dodecyl sulfate; SE-, sulfoethyl.

filtration through cheesecloth, the residue is once more extracted with 1 liter of 1 M KCl.

The extracts are combined and cooled to 4°C. Solid ammonium sulfate is added to produce approximately 40% 5 saturation (230 g per liter). After 30 min. the solution is centrifuged and 125 g of ammonium sulfate is then added per liter of supernatant (60% saturation). After centrifugation the precipitate is dissolved in 500 ml of a solution containing 5 mM Tris (pH 7.5), 0.1 mM CaCl₂, and 0.1 mM DTT 10 and dialyzed against 15 liters of the same solution for 6 hours and against a fresh solution overnight.

Solid KCl is added to a final concentration of 1 M and 1 M KCl solution is added to bring the volume to 1 liter. The pH is then adjusted to 4.6 by addition of HCl, and the 15 tropomyosin precipitate is removed by centrifugation. The pH of the supernatant is adjusted to 7.0 with KOH, and 450 g of ammonium sulfate were added per liter (70% saturation). The precipitate is dissolved in a solution containing 5 mM Tris (pH 7.5, 0.1 mM CaCl₂, and 0.1 mM DTT, and dialyzed overnight 20 against the same solution. Solid KCl is added to bring its concentration to 1 M, the pH adjusted to 4.6, and the precipitate formed removed by centrifugation. The neutralized supernatant is dialyzed against 2 mM Tris (pH 7.5) until the Nessler reaction is negative. The final yield 25 of troponin is usually 2.5 to 3.0 g per kg of fresh muscle.

Cardiac Troponin Isolation from Tissue

Bovine hearts are obtained approximately 30 min. after death and immediately cut open, rinsed of blood, and 30 immersed in ice. The left ventricle is removed, trimmed of excess fat and connective tissue, and ground. All subsequent extraction and preparation steps are performed at 0-3° except where noted. The ground muscle (500 g) is homogenized in a Waring Blender for 1 min. in 2.5 liters of solution 35 containing 0.09 M KH₂PO₄, 0.06 M K₂HPO₄, 0.3 M KCl, 5 mM 2-mercaptoethanol, pH 6.8. The homogenized muscle suspension is then stirred for 30 min. and centrifuged at 1000 x g for

20 min. The precipitate is re-extracted for 30 min. and centrifuged. The residue is then washed with 2.5 liters of 5 mM 2-mercaptoethanol and centrifuged at 1000 x g for 10 min., followed by two successive washings and centrifugations with 5 1.5 liters of 50 mM KCl, 5mM Tris-HCl (pH 8.1/5), mM 2- mercaptoethanol. The residue is then washed and centrifuged twice with 1.5 liters of 50 mM Tris-HCl (pH 8.1), and 5 mM 2- mercaptoethanol.. The volume of the residue is measured, and the residue is mixed with 0.5 volume of 3 M KCl, 50 mM Tris-
10 HCl (pH 8.1), and 5 mM 2-mercaptoethanol. After a 16- to 20- hour extraction at 0°, the suspension is centrifuged at 15,000 x g for 10 min. The sediment is discarded, and the supernatant is adjusted to pH 7.6 with 0.05 N HCl. The filamentous precipitate which forms upon pH adjustment is
15 removed by filtering the extract through nylon gauze. The protein that precipitates between 30 and 50% ammonium sulfate saturation is collected, dissolved in a solution containing 1 M KCl, and 1mM potassium phosphate (pH 6.8), and 5 mM 2- mercaptoethanol, and dialyzed against the same solution for 4
20 hours and against a fresh solution overnight. The protein solution is clarified by centrifugation at 105,000 x g for 30 min. The troponin is then purified by chromatography on a hydroxylapatite column with the protein being eluted between 0.08 and 0.10 M phosphate. Greaser et al., 1972 *Cold Spring*
25 *Harbor Symp. Quant. Biol.* 37:235-244. Rabbit cardiac troponin is prepared in a similar manner using a pooled batch of hearts which has been stored at -20°C prior to extraction.

The troponin subunits are separated by DEAE- Sephadex chromatography in 6 M urea. Bovine cardiac
30 tropomyosin is prepared from the 50% ammonium sulfate saturation supernatant from the troponin extraction scheme (see above). Ammonium sulfate is added to 65% saturation, and the precipitate is dissolved in and dialyzed versus 1 M KCl, 1 mM potassium phosphate (pH 7.0), and 5 mM 2- mercaptoethanol.
35 The protein is then purified by hydroxylapatite chromatography.

Protein Determination - Protein concentrations are determined by the biuret method of Gornall et al. using bovine serum albumin as a standard. Gornall et al., 1949, *J. Biol. Chem.*, 177:751-766.

5 **Separation of Components** - A sequence of SP-Sephadex and DEAE-Sephadex chromatography gives complete separation of the three cardiac troponin components.

Recombinant Troponin Isolation and Reconstitution Protocols

10 **Troponin I and T**

DNA encoding various troponin subunits and isoforms are known in the art. See, e.g., Wu et al., 1994, *DNA Cell. Biol.* 13:217-233; Schreier et al., 1990, *J. Biol. Chem.* 265:21247-21253; and Gahlmann et al., 1990, *J. Biol. Chem.*

15 265:12520-12528.

To express a troponin subunit, DNA encoding the subunit is subcloned into a high copy number expression plasmid, such as KP3998, using recombinant techniques known in the art.

20 To express the cloned cDNA, *E. coli* transformed with the insert-containing pKP1500 vector is grown overnight at 37°C, then inoculated into 4 liters of Luria-Bertani broth (LB) medium and grown at 42°C until mid-log phase. Isopropyl-1-thio-β-D-galactopyranoside is then added to 0.5 mM, and the 25 culture is allowed to grow at 42°C overnight. Purification of expressed troponin subunit, fragment, or analog may be adapted from published procedures (Reinach et al., 1988, *J. Biol. Chem.* 250:4628-4633 and Xu et al., 1988, *J. Biol. Chem.* 263:13962-13969). The cells are harvested by centrifugation 30 and suspended in 20 ml of 20 mM Tris, 20% sucrose, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 mg/ml lysozyme, pH 7.5. After incubation on ice for 30 min., 80 ml of 20 mM Tris, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM DTT is added and the cells broken in a French press (SLM 35 Instruments). The cell debris is pelleted; the supernatant is made 35% in saturated (NH₄)₂SO₄ and stirred on ice for 30 min. After sedimentation, the supernatant is made 50 mM in

NaCl, 5 mM in CaCl₂, 1 mM in MgCl₂, and 1 mM in DTT and then loaded onto a 1.5 X 25-cm phenyl-Sepharose (Pharmacia LKB Biotechnology Inc.) column. The column is washed first with 50 mM Tris, 50 mM NaCl, 5 mM CaCl₂, 1 mM MgCl₂, 1 mM DTT, pH 5 7.5, then with 50 mM Tris, 1 mM NaCl, 0.1 mM CaCl₂, 1 mM DTT, pH 7.5, until no more protein is eluted. The crude troponin subunit is then eluted with 50 mM Tris, 1 mM EDTA, 1 mM DTT, pH 7.5. Fractions that contained troponin subunit, fragment, or analog are pooled, dialyzed against 25 mM Tris, 6 M urea 10 (United States Biochemical Corp.), 1 mM MgCl₂, 1 mM DTT, pH 8.0, and loaded onto a 1.5 X 25-cm DE52 (Whatman) column. The column is eluted with a 0-0.6 M NaCl linear gradient. Troponin subunit, fragment, or analog eluted from the column is dialyzed against 0.1 mM NH₄HCO₃, 1 mM β-mercaptoethanol, 15 lyophilized, and stored. Purity is assessed by SDS-polyacrylamide gel electrophoresis and UV spectrophotometry. Typical yields of 6 mg of purified recombinant troponin subunit, fragment, or analog/liter of bacterial culture are expected.

20 The lyophilized recombinant protein is resuspended in a take up buffer consisting of 6M urea, 20 mM Hepes (pH 7.5), 0.5M NaCl, 2mM EDTA, and 5mM DTT. The mixture is nutated at room temperature for 1 hour. The solution is then dialyzed at 4°C for six hours with 1 exchange against a 25 dialysis buffer consisting of 0.5M NaCl, 20mM Hepes (pH 7.5), and 0.5mM DTT.

Protein concentration is determined for each subunit at 280λ. The extension coefficient of Troponin I is 0.40 and Troponin T is 0.50.

30

Troponin C

The lyophilized recombinant protein is resuspended in a take up buffer consisting of 0.1 M NaCl, 20 mM Hepes (pH 7.5), 2mM EDTA, and 5mM DTT. This solution is dialyzed for 6 35 hours at 4°C with one exchange against a dialysis buffer of 0.1 M NaCl, 20 mM Hepes (pH 7.5), and 0.5 mM DTT.

Protein concentration is determined by measuring absorbance at 280 λ . The extension coefficient for troponin C is 0.18.

5 Reconstitution of Combined Subunits:

Protein concentrations having the same reconstitution molar ratios of troponin subunits C, I, and T are maintained for all various combinations. These concentrations of the respective proteins are combined in a 10 reconstitution buffer consisting of 0.1 M NaCl, 0.1 M CaCl₂, 5 mM DTT, 5 mM Hepes (pH 7.5). Dialysis is for 20-24 hours at 4°C with three exchanges over a dialysis buffer consisting of 0.1 M NaCl, 0.1 M CaCl₂, 0.5 mM DTT, and 5 mM Hepes (pH 7.5).

Protein concentration is approximated by measuring 15 absorption at 278 λ . The troponin trimer has an extension coefficient of 0.45 at 278 λ .

Example 2: Inhibition of Endothelial Cell Proliferation measured by DNA synthesis.

20 The inhibitory effect of troponin subunit, fragment, or analog on the proliferation of bFGF-stimulated EC can be measured according to the following procedure.

Endothelial cell DNA Synthesis:

25 On day one, 5,000 Bovine capillary endothelial cells in DMEM/10% CS/1% GPS are plated onto each well of a 96-well pregelatinized tissue culture plate. On day two, the cell media is changed to DMEM, 2% CS, 1% GPS, 0.5% BSA (complete medium), supplemented with 10 μ l of 1mg/ml "cold" thymidine per 50 ml of medium. On day three, test samples in 30 complete medium are added in duplicate. Additionally, bFGF is added in each well except for the appropriate controls, to a final concentration of 0.2 ng/well. On day four, 5 μ l of 1:13 diluted ³H-Thymidine stock is added to each well and the plate is incubated for 5-6 hours. Following incubation, the 35 medium is aspirated, and the remainder is rinsed once with PBS, then twice for 5 minutes each with methanol followed by

two rinses each for 10 minutes with 5% TCA. The cells well contents are then rinsed with water three times, dried to the plate, and 100 μ l of 0.3 N NaOH is added to each well. The contents of the well are then transferred to the scintillation counter vials and 3 mls of Ecolume added to each vial. Samples are then counted on the scintillation counter.

3T3 Cell DNA Synthesis:

DNA synthesis in bFGF-stimulated 3T3 cells provides 10 a control with which to evaluate results obtained for bFGF stimulated endothelial cell proliferation. DNA synthesis in the 3T3 cells can be determined according to the following method.

BALB/c 3T3 cells are trypsinized and resuspended at 15 a concentration of 5 X 10⁴ cells/ml. Aliquots of 200 μ l are plated into 0.3 cm² microtiter wells (Microtest II tissue Culture Plates, Falcon). After reaching confluence, in a period of 2 to 3 days, the cells are further incubated for a minimum of 5 days in order to deplete the media of growth 20 promoting factors. These growth conditions yield confluent monolayers of non-dividing BALB/c 3T3 cells. Test samples are dissolved in 50 μ l of 0.15 M NaCl and added to microtiter wells, along with [³H]TdR. After an incubation of at least 24 hours, the media is removed and the cells are washed in PBS. 25 Fixation of the cells and removal of unincorporated [³H]TdR is accomplished by the following successive steps; addition of methanol twice for periods of 5 minutes, 4 washes with H₂O, addition of cold 5% TCA twice for periods of 10 minutes, and 4 washes with H₂O. DNA synthesis is measured either by liquid 30 scintillation counting or by autoradiography using a modification of the method described by Haudenschild et al., 1976, *M. Exp. Cell Res.* 98:175. For scintillation counting, cells are lysed in 150 μ l of 0.3 N NaOH and counted in 5 ml. of Insta-Gel liquid scintillation cocktail (Packard) using a 35 Packard Tri-Carb liquid scintillation counter. Alternatively, autoradiography may be used to quantitate DNA synthesis by punching out the bottoms of the microtiter wells

and mounting them on glass slides with silastic glue. The slides are dipped in a 1 g/ml solution of NTB2 nuclear track emulsion (Kodak) and exposed for 3-4 days. The emulsion is developed with Microdol-X solution (Kodak) for 10 minutes, 5 rinsed with distilled H₂O, and fixed with Rapid Fixer (Kodak) for three minutes. The autoradiographs are stained with a modified Giemsa stain. At least 1000 nuclei are counted in each well and DNA synthesis, expressed as the percentage of nuclei labeled. Cell division is measured by counting the 10 number of cells in microtiter wells with the aid of a grid after 40-48 hour incubations with test samples.

15 **Example 3: Inhibition of Endothelial Cell
Proliferation measured by colorimetric
determination of cellular acid phosphatase
activity and electronic cell counting**

A quick and sensitive screen for inhibition of EC proliferation in response to treatment with a troponin subunit, analog, or derivative of the invention involves incubating the cells in the presence of varying 20 concentrations of the inhibitor and determining the number of endothelial cells in culture based on the colorimetric determination of cellular acid phosphatase activity, described by Connolly, et al., 1986, *J. Anal. Biochem.* 152:136-140.

25 We measured the effect of troponin on the proliferation of capillary endothelial cells (EC) in an assay which measures the ability of this protein to interfere with stimulation of endothelial cell proliferation by a known angiogenesis factor (bFGF).

30 Capillary endothelial cells and Balb/c 3T3 cells were separately plated (2×10^3 /0.2 ml) onto gelatin-coated 96-well tissue culture dishes on day 1. On day 2, cells were refed with Dulbecco's modified Eagle's medium (Gibco) with 5% calf serum (Hyclone) (DMEM/5) and bFGF (10 ng/ml) (FGF Co.) 35 and increasing concentrations of the troponin subunit. These substances were added simultaneously in volumes that did not exceed 10% of the final volume. Wells containing phosphate

buffered saline (PBS) (Gibco) alone and PBS + bFGF were included as controls. On day 5, media was removed and cells were washed with PBS and lysed in 100 μ l of buffer containing 0.1 M sodium acetate (pH 5.5), 0.1% Triton X-100™ and 100 mM 5 p-nitrophenyl phosphate (Sigma 104 phosphatase substrate). After incubation for 2 hours at 37°C, the reaction was stopped with the addition of 10 μ l of 1 N NaOH. Color development was determined at 405 nm using a rapid microplate reader (Bio-Tek).

10 Percent inhibition was determined by comparing the cell number of wells exposed to stimulus with those exposed to stimulus and troponin subunits.

15 All three troponin subunits were found to inhibit bFGF-stimulated EC proliferation, as measured by the colorimetric assay.

Troponin C inhibited bFGF-stimulated endothelial cell proliferation in a dose-dependent manner in all concentrations tested (FIG 1). Percent inhibition of bovine endothelial cell proliferation ("BCE") was 54%, 86%, 83%, and 20 100% at concentrations of 280 nM, 1.4 μ M, 2.8 μ M and 5.6 μ M, respectively. An inhibition of 100% was observed at a concentration of 20 ug/well (5.6 μ M). IC₅₀ represents the concentration at which 50% inhibition of bFGF growth factor-induced stimulation was observed. The IC₅₀ of troponin C was 25 determined to be 278 nM.

Troponin I inhibited bFGF-stimulated BCE proliferation at concentrations of 1 and 5 ug/well, but inhibition was not observed in the sample tested at 10 ug/well (FIG 2). The percent inhibition of BCE was 33% and 30 46% at concentrations of 240 nM and 1.2 μ M, respectively. The IC₅₀ of troponin I was determined to be 1.14 μ M.

Troponin T inhibited bFGF-stimulated EC proliferation at concentrations of 10 and 20 ug/well, but not at concentrations of 1 and 5 μ g/well (FIG 3). BCE 35 proliferation was inhibited 23% and 62% at 1.6 μ M and 3.3 μ M, respectively. The IC₅₀ of troponin T was determined to be 2.14 μ M.

The combination of troponin subunits C and I inhibited EC at all concentrations tested (FIG 4). The percent inhibition of proliferation of BCE was 52%, 54% 73% and 47% at 130 nM, 645 nM, 1.3 μ M and 2.6 μ M, respectively.

5 The IC₅₀ of this combination was determined to be 110 nM.

The combination of troponin subunits C, I and T was observed to inhibit bFGF-stimulated BCE proliferation by 16% at a concentration of 360 nM (5 ug/well, FIG 5).

10 The troponin samples tested had no detectable inhibitory effect on the growth of Balb/c 3T3 cells, a non-endothelial cell type.

Example 4: Inhibition of Capillary Endothelial Cell Migration by troponin

15 Determination of the ability of the troponin subunit, derivative, or analog to inhibit the angiogenic process of capillary EC migration in response to an angiogenic stimulus, can be determined using a modification 20 of the Boyden chamber technique is used to study the effect of troponin subunit, derivative, or analog on capillary EC migration. Falk et al., 1980, *J. Immunol.* 118:239-247 (1980). A blind-well Boyden chamber, consists of two wells (upper and lower) separated by a porous membrane. *J. Exp. Med.* 115:453-456 (1962). A known concentration of growth 25 factor is placed in the lower wells and a predetermined number of cells and troponin subunit, derivative, or analog is placed in the upper wells. Cells attach to the upper surface of the membrane, migrate through and attach to the lower membrane surface. The membrane can then be fixed and 30 stained for counting, using the method of Glaser et al., 1980, *Nature* 288:483-484.

Migration is measured using blind well chambers (Neuroprobe, no. 025-187) and polycarbonate membranes with 8 35 micron pores (Nucleopore) precoated with fibronectin (6.67 μ g/ml in PBS) (human, Cooper). Basic FGF (Takeda Co.) diluted in DMEM with 1% calf serum (DMEM/1) is added to the

lower well at a concentration of 10 ng/ml. The upper wells receive 5×10^5 capillary EC/ml and increasing concentrations of purified troponin subunit, derivative or analog is used within 24 hours of purification. Control wells receive 5 DMEM/l, either with or without bFGF. The migration chambers are incubated at 37°C in 10% CO₂ for 4 hours. The cells on the upper surface of the membrane are then wiped off by drawing the membrane over a wiper blade (Neuroprobe). The cells which have migrated through the membrane onto the lower 10 surface are fixed in 2% glutaraldehyde followed by methanol (4°C) and stained with hematoxylin. Migration is quantified by counting the number of cells on the lower surface in 16 oil immersion fields and comparing this number with that obtained for the control.

15

Example 5: Inhibition of tumor growth as determined by a SCID mouse model system

The effects of recombinant troponin I on the growth of human PC-3 prostatic carcinoma cells were determined in 20 immunodeficient (SCID) mice in a treatment and a control group of four mice each. A dorsal subcutaneous implantation of 10^6 PC-3 cells was made and observed until a volume of between 100-400 mm³ was attained. After the tumor reached the threshold volume, twice daily subcutaneous injections of 25 50mg/kg recombinant troponin I was begun in the treatment group.

Figure 6 shows that 28 days of treatment resulted in an approximate 50% reduction in tumor volume in the treatment group compared to the tumor volume of the control group.

30

Example 6: Inhibition in vivo of Neovascularization by troponin as determined by the murine corneal pocket assay

A pellet of sucrose octasulfate, Hydron™ and basic 35 Fibroblast Growth Factor (40 ng/pellet) was placed in a corneal micropocket of a mouse. The mouse received

subcutaneous injections of recombinant Troponin I, 50 mg/kg every 12 hours beginning 48 hours prior to the implantation.

Corneal angiogenesis was evaluated by slit lamp microscopy. By day 6 angiogenesis in control eyes results in vessels that have extended into the pellet by day 6. At this time there was observed a 50% reduction in blood vessel density and a 30% inhibition in blood vessel length in the treated animals.

10

15

20

25

30

35

WE CLAIM:

1. A pharmaceutical composition comprising an amount of a peptide that is effective to inhibit 5 angiogenesis, in which the peptide is:

- a. an inhibitor of bFGF-stimulated bovine endothelial cell proliferation having an IC₅₀ of at least 10 μM;
- b. greater than 75 amino acids in length; 10 and
- c. greater than 80% homologous with a subunit selected from the group consisting of human fast-twitch troponin subunit C (SEQ ID NO:1), human fast-twitch troponin subunit I (SEQ ID NO:2), and human fast-twitch troponin subunit T (SEQ ID NO:3); and 15

a pharmaceutically acceptable carrier.

20 2. The composition of claim 1, in which the subunit is human fast-twitch troponin C or human fast-twitch troponin I.

25 3. The composition of claim 1, in which the subunit is human fast-twitch troponin C.

4. The composition of claim 1, in which the subunit is human fast-twitch troponin I.

30 5. The composition of claim 1 in which the peptide is greater than 95 % homologous with a human troponin subunit.

35 6. The composition of claim 5, in which the subunit is human fast-twitch troponin C.

7. The composition of claim 5, in which the subunit is human fast-twitch troponin I.

8. The composition of claim 1 in which the 5 peptide is a mammalian troponin subunit.

9. The composition of claim 8 in which the peptide is a mammalian troponin C or troponin I subunit.

10 10. The composition of claim 9 in which the peptide is a troponin subunit selected from the group consisting of bovine, rabbit, mouse and rat troponin subunits.

15 11. The composition of claim 8 in which the peptide is a human troponin C or troponin I subunit.

12. The composition of claim 8 in which the peptide is a troponin subunit selected from the group 20 consisting of bovine, rabbit, mouse and rat troponin subunits.

13. The composition of claim 1 in which the peptide is a fragment of a mammalian troponin subunit.

25 14. The composition of claim 13 in which the peptide is a fragment of a human troponin C or troponin I subunit.

30 15. The composition of claim 13 in which the peptide is a fragment of a troponin I or troponin C subunit selected from the group consisting of bovine, rabbit, mouse and rat troponin C and I subunits.

35 16. The composition of claim 1 wherein the carrier is acceptable for topical application to the eye.

17. The composition of claim 1 wherein the carrier is acceptable for topical application to the skin.

18. The composition of claim 1 wherein the 5 angiogenesis inhibitor is in a biodegradable, biocompatible polymeric delivery device.

19. A method of inhibiting atopic angiogenesis in a subject, having a disease or disorder causing atopic 10 angiogenesis requiring such inhibition, which comprising the step of applying to a site of atopic angiogenesis an amount of a peptide that is effective to inhibit angiogenesis, in which the peptide is:

- a. an inhibitor of bFGF-stimulated bovine 15 endothelial cell proliferation having an IC₅₀ of at least 10 μM;
- b. greater than 75 amino acids in length; and
- c. greater than 80% homologous with a 20 subunit selected from the group consisting of human fast-twitch troponin I subunit, human fast-twitch troponin C subunit and human fast-twitch troponin T subunit.

25

20. The method of claim 19, in which the subunit is human fast-twitch troponin C or human fast-twitch troponin I.

30

21. The method of claim 20, in which the disease or disorder is a solid tumor.

22. The method of claim 20, in which the tumor is a tumor of the central nervous system.

35

23. The method according to claim 20, in which the disease or disorder is an ophthalmologic disease or disorder.

1/6

Tn C




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/02439

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 14/ 47, 14/ 435; A61K 35/ 34

US CL : 514/2, 21; 530/324, 350,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 21; 530/324, 350,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS,CAS ONLINE, STN

search terms: troponin, subunit, fragment, composition, angiogenesis, proliferation

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 5,583,200 (LARUE ET AL) 10 December 1996, column 1, line 67, see Abstract, claim 1.	1-12, 16-18
X	TANOKURA, M. et al. Interactions among chymotryptic troponin T subfragments, tropomyosin troponin I and troponin C. Journal of Biochem., 1984, Vol. 95, No. 5, page 1417-1421, see Abstract.	13-15
X	GRABAREK et al. Proteolytic fragments of Troponin C. Journal of Biol. Chem. 1981, Vol. 256, pages 13121-13127, see Abstract,	13-15

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 13 MAY 1997	Date of mailing of the international search report 05 JUN 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer MICHAEL L. BORIN Telephone No. (703) 308-0196

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.